
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>British Society of Gastroenterology practice guidance on the management of acute and chronic gastrointestinal symptoms and complications as a result of treatment for cancer</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>British Society of Gastroenterology practice guidance on the management of acute and chronic gastrointestinal symptoms and complications as a result of treatment for cancer</strong></summary>
            <div>
                <ul><li>Journal: Gut</li><li>Publication Date: 2025 (Epub ahead of print)</li><li>DOI: 10.1136/gutjnl-2024-333812</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What percentage of patients on lenalidomide develop bile acid diarrhoea, and what is the median time to onset?</li><li>2. In patients with severe capecitabine/5-FU GI toxicity, what imaging is urgently required and what condition must be excluded?</li><li>3. What is the recommended starting dose of Pancreatic Enzyme Replacement Therapy (PERT) for suspected PEI, in units of lipase?</li><li>4. Argon plasma coagulation for radiation proctopathy carries a serious complication rate of up to what percentage?</li><li>5. What two patient factors, identifiable before radiotherapy, increase the risk of acute GI toxicity?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Patient Perspectives</strong></summary>
            <div>
                <ul><li>Emphasizes the importance of the patient&#x27;s experience and needs.</li><li>All clinicians have a responsibility to identify unmet needs &amp; signpost patients.</li><li>Continued holistic assessment is recommended before &amp; after cancer treatment.</li></ul>
                
        <details>
            <summary><strong>Key Recommendations</strong></summary>
            <div>
                <ul><li>Inform all patients about possible future side effects &amp; how to access help.</li><li>Use a personalised care and support plan at the end of treatment.</li><li>Listen to patient concerns &amp; signpost to appropriate services.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Holistic Needs Assessment</strong></summary>
            <div>
                <ul><li>Highlights problems beyond physical symptoms: emotional, social, occupational, financial.</li><li>Useful at diagnosis, on treatment completion, and during follow-up.</li><li>Data from 18,000 patients shows top concerns: questions about diagnosis/treatment, thinking about the future, partner, uncertainty.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Patient Experience</strong></summary>
            <div>
                <ul><li>Ongoing, unacknowledged symptoms have a negative impact on life.</li><li>Quotes illustrate impact: &#x27;My bowel issues are the first thing I think about in the morning and the last thing I think about at night.&#x27;</li><li>Patients often feel they are in a &#x27;lonely place&#x27; post-treatment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Trigger Questions for Referral</strong></summary>
            <div>
                <ul><li>Simple questions to identify patients needing gastroenterology referral.</li><li>A &#x27;Yes&#x27; to any should lead to an offer of referral.</li></ul>
                
        <details>
            <summary><strong>Screening Questions</strong></summary>
            <div>
                <ul><li>1. Do you have frequent loose stools?</li><li>2. Do you wake up at night needing to poo?</li><li>3. Do you have leakage from your bottom?</li><li>4. Do you have blood in your stools/rectal bleeding?</li><li>5. Is your quality of life reduced owing to your bowel function?</li><li>6. Has your mental health been affected by your bowel function?</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pathophysiology Overview</strong></summary>
            <div>
                <ul><li>Optimal symptom management requires identifying physiological deficits with appropriate testing.</li><li>The majority of patients developing GI symptoms after cancer treatment have &gt;1 cause.</li><li>Different treatments often cause the same symptoms via different physiological mechanisms.</li></ul>
                
        <details>
            <summary><strong>Mechanisms of Injury</strong></summary>
            <div>
                <ul><li>Cancer treatments cause pathological insults → changes in GI physiological processes → abnormal symptoms.</li></ul>
                
        <details>
            <summary><strong>Cytotoxic Chemotherapy</strong></summary>
            <div>
                <ul><li>Direct effect on rapidly proliferating GI tissues (mucosal barrier, enzyme systems) → inflammation, oedema, cell death.</li><li>Indirect damage via microvascular injury or visceral nervous system damage.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Targeted Therapies</strong></summary>
            <div>
                <ul><li>Agents target receptors (VEGF, EGFR, tyrosine kinases) also found in normal GI tissues.</li><li>GI toxicity, particularly diarrhoea, occurs in 18–95% of treated patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Radiotherapy</strong></summary>
            <div>
                <ul><li>Initial mucosal changes: inflammation &amp; oedema.</li><li>Subsequent persistent cytokine activation in submucosa → ischaemia, fibrosis, atrophy, loss of stem cells.</li><li>Damage may be progressive.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Surgery</strong></summary>
            <div>
                <ul><li>Resectional surgery causes physiological changes from denervation or reconfiguration.</li><li>Examples: vagotomy, loss of gastric/rectal reservoirs, mechanical shortening, blind loops.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Common Physiological Abnormalities</strong></summary>
            <div>
                <ul><li>Summarizes the frequency of specific physiological changes caused by different cancer therapies.</li></ul>
                
        <details>
            <summary><strong>During Chemotherapy</strong></summary>
            <div>
                <ul><li>Lactose intolerance: 5–10%</li><li>Bile acid malabsorption: Yes (frequency unknown)</li><li>Small bowel bacterial overgrowth (SIBO): Yes</li><li>Pancreatic insufficiency (PEI): Yes</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>During Radiotherapy</strong></summary>
            <div>
                <ul><li>Lactose intolerance: 50%</li><li>Bile acid malabsorption: 50%</li><li>SIBO: 25%</li><li>Rapid transit: 100%</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>After Radiotherapy</strong></summary>
            <div>
                <ul><li>Lactose intolerance: 5–7%</li><li>Bile acid malabsorption: 1–83%</li><li>SIBO: 8–45%</li><li>Rapid transit: 100%</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>After Upper GI Surgery</strong></summary>
            <div>
                <ul><li>Malabsorption of disaccharides: Yes</li><li>Bile acid malabsorption: Yes</li><li>SIBO: Yes</li><li>PEI: Yes</li><li>Rapid transit: Yes</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>GI Symptoms &amp; Patient-Centred Assessment</strong></summary>
            <div>
                <ul><li>Use validated symptom questionnaires (e.g., GSRS) or PROMs.</li><li>In curative-intent patients, recurrence must be considered and ruled out.</li><li>Consider investigations for conditions not associated with the cancer or its treatment.</li></ul>
                
        <details>
            <summary><strong>Symptom Assessment</strong></summary>
            <div>
                <ul><li>Individual symptoms &amp; symptom clusters are unreliable for diagnosing the underlying cause.</li><li>&gt;30 different GI symptoms can develop.</li><li>Different physiological disorders can cause similar symptoms (e.g., bloating can be from BAD, carbohydrate malabsorption, PEI, or SIBO).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Validated Tools</strong></summary>
            <div>
                <ul><li>Use of questionnaires ensures the patient&#x27;s perspective is captured.</li><li>Examples: Gastrointestinal Symptom Rating Scale (GSRS), EORTC QLQ-CR29, PRO-CTCAE.</li><li>Visual aids (Visual Analogue Scales, Bristol Stool Chart) support clinical decision-making.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Tests</strong></summary>
            <div>
                <ul><li>Clinical acumen or symptom patterns are unreliable for diagnosis in this population.</li><li>Comprehensive investigation is required early if symptoms don&#x27;t respond to simple, empirical intervention.</li><li>Early advice from a gastroenterologist should be sought for ongoing or severe toxicity.</li></ul>
                
        <details>
            <summary><strong>Common Treatable Conditions</strong></summary>
            <div>
                <ul><li>A wide variety of cancer treatments cause the same physiological changes.</li><li>Frequently include: Bile acid diarrhoea (BAD), carbohydrate intolerance, pancreatic exocrine insufficiency (PEI), small intestinal bacterial overgrowth (SIBO).</li><li>After immunosuppression, consider bacterial or viral infection.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Timing of Investigations</strong></summary>
            <div>
                <ul><li>Investigating acutely during chemotherapy/radiotherapy is feasible and beneficial if symptoms impact treatment.</li><li>Randomised trials show a systematic approach is beneficial in both acute and chronic settings.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Symptom-Specific Test Suggestions</strong></summary>
            <div>
                <ul><li>A structured approach to investigating common GI symptoms.</li></ul>
                
        <details>
            <summary><strong>Steatorrhoea</strong></summary>
            <div>
                <ul><li>Test 1: Faecal elastase → if abnormal, trial PERT.</li><li>Test 2: SeHCAT study → if abnormal, treat for BAD.</li><li>Test 3: Glucose H2/CH4 breath test / SI aspiration → if abnormal, treat for SIBO.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diarrhoea (± urgency</strong><br><em>)</em></summary>
            <div>
                <ul><li>Test 1: Faecal elastase, calprotectin, FIT, stool microbiology, sigmoidoscopy + biopsies → if abnormal, treat accordingly (PERT, microscopic colitis, infection).</li><li>Test 2: SeHCAT study → if abnormal, treat for BAD.</li><li>Test 3: Glucose H2/CH4 breath test / SI aspiration → if abnormal, treat for SIBO.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Constipation</strong></summary>
            <div>
                <ul><li>Test 1: FIT, Abdominal X-ray (AXR) → check for impaction/obstruction.</li><li>Test 2: Transit study.</li><li>Test 3: Colonoscopy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Upper Abdominal Pain</strong></summary>
            <div>
                <ul><li>Test 1: H. pylori test.</li><li>Test 2: Glucose H2/CH4 breath test.</li><li>Test 3: OGD + aspirate, Biliary US.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Bloating/Flatulence/Belching</strong></summary>
            <div>
                <ul><li>Test 1: Faecal calprotectin, FIT, Faecal elastase.</li><li>Test 2: Glucose H2/CH4 breath test / SI aspiration.</li><li>Test 3: Flexible sigmoidoscopy/colonoscopy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Commonly Occurring Conditions: Diagnosis &amp; Treatment</strong></summary>
            <div>
                <ul><li>In patients on restrictive diets, consider daily long-term trace elements &amp; multivitamin supplements.</li><li>If long-term dietary interventions are recommended, arrange dietetic review.</li><li>If multiple diagnoses, introduce treatments one at a time &amp; document symptom response.</li></ul>
                
        <details>
            <summary><strong>Bile Acid Diarrhoea/Malabsorption (BAD/BAM)</strong></summary>
            <div>
                <ul><li>Common after many oncological treatments.</li><li>Definitive diagnosis: SeHCAT scan.</li></ul>
                
        <details>
            <summary><strong>Treatment by Severity (SeHCAT 7-day retention)</strong></summary>
            <div>
                <ul><li>Mild (10–20%): Long-term low-fat diet may be sufficient.</li><li>Moderate (5–10%): Bile sequestrant.</li><li>Severe (0–5%): Sequestrant + low-fat diet.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Bile Sequestrants</strong></summary>
            <div>
                <ul><li>No licensed treatments for BAD/BAM.</li><li>Options: Colestyramine, colestipol, colesevelam.</li><li>Colesevelam: more effective, better tolerated, fewer interactions.</li><li>Start low dose, take with meals, titrate slowly to improve tolerance.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Monitoring</strong></summary>
            <div>
                <ul><li>Vitamin D deficiency occurs in 20% of patients on sequestrants.</li><li>Rarely, can develop significant hypertriglyceridaemia and/or vitamin A, E, K deficiency.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Small Intestinal Bacterial Overgrowth (SIBO)</strong></summary>
            <div>
                <ul><li>Occurs very commonly during and after cancer treatment.</li><li>Testing is recommended over empirical treatment to aid antibiotic stewardship.</li><li>Multiple diagnoses often coincide, making empirical trials confusing.</li></ul>
                
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Glucose or lactulose breath tests can be helpful.</li><li>Adding methane to hydrogen breath analysis ↑ accuracy.</li><li>Qualitative small bowel aspiration during endoscopy is a practical option.</li></ul>
                
        <details>
            <summary><strong>Aspirate Technique</strong></summary>
            <div>
                <ul><li>1. On intubation, avoid aspirating.</li><li>2. Flush 100 mL sterile saline into duodenum.</li><li>3. Flush channel with 10 mL air.</li><li>4. Aspirate ≥10 mL into a sterile trap.</li><li>5. Positive aspirates will grow colonic bacteria.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>Rifaximin 550 mg BID for 1–2 weeks is effective in ≈60–80% of patients.</li><li>Other options: doxycycline, ciprofloxacin, amoxicillin–clavulanic acid.</li><li>Recurrent SIBO: low-dose, long-term, cyclical, or recurrent short course antibiotics.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pancreatic Exocrine Insufficiency (PEI)</strong></summary>
            <div>
                <ul><li>Best diagnosed by faecal elastase-1 measurement.</li><li>Faecal elastase &lt;500 µg/g may indicate PEI, untreated coeliac disease, SIBO, or a watery stool sample.</li></ul>
                
        <details>
            <summary><strong>When to Treat Empirically</strong></summary>
            <div>
                <ul><li>Common in pancreatic cancer &amp; after pancreatico-duodenal resection.</li><li>Frequently develops after starting somatostatin analogues for NENs.</li><li>In these situations, a trial of PERT is appropriate without testing.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>PERT Dosing</strong></summary>
            <div>
                <ul><li>A 10-day trial is usually sufficient to assess efficacy.</li><li>Start at 50,000 units of lipase with meals &amp; 25,000 with snacks.</li><li>Increase dose if symptoms persist or weight is not maintained.</li><li>If PERT is not tolerated, it often indicates underlying SIBO.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Carbohydrate Intolerance</strong></summary>
            <div>
                <ul><li>Lactose intolerance may be induced by chemotherapy/radiotherapy.</li><li>May resolve within weeks after treatment ends.</li><li>Requires eliminating only lactose-containing products, not a complete dairy-free diet to avoid nutritional deficits.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pelvic Floor Dysfunction</strong></summary>
            <div>
                <ul><li>Evidence for interventions is poor.</li><li>Management includes bowel habit training, toilet positioning, modifying stool consistency.</li><li>Faecal incontinence may respond to pelvic floor muscle training &amp; firming stool with loperamide.</li></ul>
                
        <details>
            <summary><strong>Constipation Management</strong></summary>
            <div>
                <ul><li>Affects 40–90% with advanced cancer or on opioids.</li><li>Prevention is key: prophylactic laxatives when opioids are prescribed.</li><li>PAMORAs (peripherally acting mu opioid receptor antagonists) are effective; conventional laxatives are first-line.</li><li>Consider faecal impaction &amp; overflow as a cause of apparent diarrhoea.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Transanal Irrigation</strong></summary>
            <div>
                <ul><li>Can be effective when other treatments fail.</li><li>Especially in passive incontinence, severe constipation, and anterior resection syndrome.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>GI Infection</strong></summary>
            <div>
                <ul><li>Risk is ↑ in immunosuppressed patients.</li><li>Loperamide can be given safely before microbiology results are available, but reassess for toxic dilatation.</li></ul>
                
        <details>
            <summary><strong>Bacterial</strong></summary>
            <div>
                <ul><li>C. difficile: Pseudomembranes may not be seen in neutropenic patients. Endoscopic biopsy can diagnose C. difficile colitis in this context.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Viral</strong></summary>
            <div>
                <ul><li>Multiple GI ulcers should raise suspicion of CMV or HSV.</li><li>For CMV, immunocytochemistry and PCR of biopsy samples are helpful. Blood-based PCR is insensitive.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Fungal</strong></summary>
            <div>
                <ul><li>Fungal overgrowth in the small bowel is intermittently identified.</li><li>May cause SIBO-like symptoms and has been associated with ↑ risk of bowel perforation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pain Management</strong></summary>
            <div>
                <ul><li>Chronic pain after surgery/radiotherapy may be from stricture, adhesions, or fibrosis.</li><li>Colonic faecal loading and SIBO are under-appreciated causes.</li><li>New or unexplained pain →</li><li>consider tumour recurrence.</li></ul>
                
        <details>
            <summary><strong>Acute/Severe Pain</strong></summary>
            <div>
                <ul><li>Signs of complete intestinal obstruction &amp; severe abdominal pain require emergency surgical assessment.</li><li>Early CT imaging is required to understand anatomy &amp; exclude recurrence.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Chronic Pain Mechanisms</strong></summary>
            <div>
                <ul><li>Mechanical obstruction: colicky pain, worse after eating, may be associated with vomiting.</li><li>Pseudo-obstruction: obstructive symptoms w/o a defined obstruction point on imaging. Often multifactorial (dysmotility, constipation, SIBO, BAD).</li><li>Neuropathic pain: can be caused by radiotherapy, possibly due to tissue fibrosis and nerve entrapment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Multidisciplinary Approach</strong></summary>
            <div>
                <ul><li>Management requires input from gastroenterology, surgery, pain management, and nutrition teams.</li><li>Always consider localized sepsis or bone insufficiency fracture (may require MRI).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>GI Toxicity from Specific Therapies</strong></summary>
            <div>
                <ul><li>This section details GI side effects related to specific cancer treatment modalities.</li></ul>
                
        <details>
            <summary><strong>Cytotoxic Chemotherapy</strong></summary>
            <div>
                <ul><li>Frequent physiological disorders: lactose intolerance, SIBO, BAD, PEI.</li><li>Investigations during treatment are feasible &amp; beneficial.</li><li>Mortality rate from modern chemo is 1–5%, largely due to sepsis or multiorgan failure with diarrhoea.</li></ul>
                
        <details>
            <summary><strong>Acute Diarrhoea Management</strong></summary>
            <div>
                <ul><li>Perform stool analysis for infection.</li><li>It is generally safe to start loperamide while awaiting results.</li><li>Reassess regularly to exclude toxic dilatation of the colon.</li><li>Temporarily pause potentially aggravating oral anticancer drugs.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Capecitabine/5-FU Enterocolitis</strong></summary>
            <div>
                <ul><li>A rare but severe toxicity.</li><li>Patients presenting with severe GI toxicity require an urgent CT scan to exclude enterocolitis.</li><li>Associated with dihydropyrimidine dehydrogenase (DPD) deficiency (found in 3–5% of population).</li><li>Requires rapid, intensive intervention: immediate cessation of drug, IV fluids, antibiotics, consider parenteral nutrition.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Immunotherapy</strong></summary>
            <div>
                <ul><li>Diarrhoea is common and can occur at any time after treatment initiation.</li><li>Severe diarrhoea (&gt;6 stools/day over baseline) requires admission, IV corticosteroids, and urgent investigation.</li></ul>
                
        <details>
            <summary><strong>Management of Enterocolitis</strong></summary>
            <div>
                <ul><li>If no response to IV corticosteroids within 2-3 days, start second-line therapy.</li><li>Second-line: Infliximab or vedolizumab (equally efficacious).</li><li>Third-line options for refractory cases: tofacitinib, tocilizumab, ustekinumab.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Small Molecules/Targeted Agents</strong></summary>
            <div>
                <ul><li>Diarrhoea occurs in up to 95% of treated patients.</li><li>Little research exists on the physiological mechanisms.</li></ul>
                
        <details>
            <summary><strong>Specific Agent Toxicities</strong></summary>
            <div>
                <ul><li>Sorafenib: PEI is a common cause of GI symptoms, occurring in &gt;10% of patients (median onset 6 months).</li><li>Lenalidomide: BAD is a common cause of GI symptoms, occurring in 20% of patients (median onset 4 months).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Radiotherapy (RT)</strong></summary>
            <div>
                <ul><li>Toxicity is limited by tolerance of normal tissues.</li><li>Severity of acute toxicity predisposes to late toxicity.</li></ul>
                
        <details>
            <summary><strong>Risk Factors for Toxicity</strong></summary>
            <div>
                <ul><li>Smoking and low BMI (&lt;18.5 kg/m²) predict worse acute toxicity.</li><li>These should be addressed before RT if possible.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Acute RT-Induced Toxicity Prevention</strong></summary>
            <div>
                <ul><li>Dietary counselling and/or protein supplementation may reduce risk.</li><li>Lactobacilli ± bifidobacteria containing probiotics may reduce acute RT-related diarrhoea.</li><li>A high-fibre diet may reduce toxicity risk during pelvic RT.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Acute Mucositis (Oral &amp; Oesophageal)</strong></summary>
            <div>
                <ul><li>Exclude HSV, CMV, and extensive candidiasis in persistent cases.</li><li>Symptomatic treatment: modified WHO analgesia ladder.</li><li>Consider early referral to nutrition team.</li><li>Mouth washes, topical analgesics, coating agents may help.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Upper GI Tract Strictures</strong></summary>
            <div>
                <ul><li>Occur in ≈30% of patients after RT for oesophageal cancer.</li><li>Do not dilate potentially malignant strictures until recurrence is excluded or MDT approved.</li><li>Endoscopic dilatation is preferred for benign strictures; success &gt;80%.</li><li>Avoid high oesophageal stents that impinge on the cricopharyngeus.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Acute Lower GI Symptoms</strong></summary>
            <div>
                <ul><li>Usually begin in week 2, peak in the last week of treatment.</li><li>Management is empirical; antidiarrhoeals, antispasmodics may help.</li><li>Grade 3 or 4 diarrhoea mandates stopping chemotherapy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Chronic Issues After Cancer Treatment</strong></summary>
            <div>
                <ul><li>This section covers long-term GI complications following surgery and radiotherapy.</li></ul>
                
        <details>
            <summary><strong>After Upper GI Surgery</strong></summary>
            <div>
                <ul><li>Symptoms often relate to mechanical reconfiguration &amp; physiological changes.</li><li>Extensive investigation within 3 months is generally unnecessary as symptoms often settle.</li><li>Do not attribute new symptoms to IBS until organic causes are excluded.</li></ul>
                
        <details>
            <summary><strong>Common Issues &amp; Management</strong></summary>
            <div>
                <ul><li>Anastomotic stricture: Endoscopic dilatation is preferred.</li><li>Acid reflux: Treat with PPIs; prokinetics for up to 6 weeks may help.</li><li>Bile reflux: Oral sucralfate suspension may be useful.</li><li>Postprandial pain: Commonly due to eating too much at one sitting.</li><li>Bowel dysfunction/steatorrhoea: Commonly due to PEI, SIBO, and/or severe BAD. Diagnostic testing is recommended over empirical treatment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>After Pelvic Cancer Treatment (Surgery/RT)</strong></summary>
            <div>
                <ul><li>Post-pelvic cancer symptoms need to be actively identified and managed.</li><li>Multimodal treatment carries a higher risk for long-term complaints.</li></ul>
                
        <details>
            <summary><strong>Radiation-Induced Rectal Bleeding</strong></summary>
            <div>
                <ul><li>Occurs in up to 50% of patients after pelvic RT.</li><li>Cannot be assumed to be from telangiectasia; requires endoscopic/radiological investigation.</li><li>Diagnosis is based on typical appearance; biopsy should not be performed due to risk of necrosis/perforation.</li></ul>
                
        <details>
            <summary><strong>Management Strategy</strong></summary>
            <div>
                <ul><li>Intervention only if bleeding affects quality of life or causes anaemia.</li><li>Optimising irregular bowel function often reduces bleeding.</li><li>Stopping anticoagulants/antiplatelet agents (if possible) is effective.</li><li>Sucralfate enemas can be a useful temporary or long-term treatment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Interventional Therapies &amp; Risks</strong></summary>
            <div>
                <ul><li>Argon plasma coagulation: Widely used but carries a serious complication rate up to 26% (stricture, pain, perforation, fistula).</li><li>Hyperbaric oxygen (HBO): Meta-analysis suggests benefit, but trial data are contradictory.</li><li>Formalin: Appears effective in observational studies but carries risks of colitis, stricturing, and pain.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Lower GI Functional Symptoms</strong></summary>
            <div>
                <ul><li>Interventions: bowel habit training, toilet positioning, modifying stool consistency (diet, fluids, loperamide, fibre).</li><li>A large bowel transit study may help distinguish slow transit constipation from evacuation difficulty.</li><li>Reserve defaecating proctogram, endoanal ultrasound, anorectal physiology for specialist practice.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Low Anterior Resection Syndrome (LARS)</strong></summary>
            <div>
                <ul><li>Defined by symptoms like unpredictable bowel function, urgency, frequency, emptying difficulties.</li><li>Significantly impacts quality of life in 60–90% of patients.</li><li>Objective testing is not required for diagnosis.</li></ul>
                
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Offer supported self-management to all patients post-resection.</li><li>If symptoms persist &gt;3 months, refer to specialist services.</li><li>Exclude worsening conditions like BAD, PEI, SIBO.</li><li>Interventions: Pelvic floor exercises, bulking agents, transanal irrigation, stoma formation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Fistulae</strong></summary>
            <div>
                <ul><li>A rare complication; incidence is likely decreasing.</li><li>Crucial to rule out disease recurrence before assuming radiation injury.</li><li>Requires a multidisciplinary approach by a regionally based team.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Special Populations &amp; Conditions</strong></summary>
            <div>
                <ul><li>Management considerations for specific patient groups and complex syndromes.</li></ul>
                
        <details>
            <summary><strong>Haematopoietic Stem Cell Transplant (HSCT)</strong></summary>
            <div>
                <ul><li>GI toxicity predicts post-transplant complications.</li><li>A multidisciplinary approach is helpful (haematology, dietetics, gastroenterology).</li><li>For lower GI symptoms, upper GI endoscopy + flexible sigmoidoscopy is safer than colonoscopy and similarly effective.</li></ul>
                
        <details>
            <summary><strong>Diagnosis of Diarrhoea</strong></summary>
            <div>
                <ul><li>Endoscopic tests with small bowel aspirate &amp; biopsies are helpful.</li><li>Differentiates between SIBO/fungal overgrowth, infections (C. diff, CMV), and Graft versus Host Disease (GvHD).</li><li>Wireless capsule endoscopy is not recommended for diagnosing GvHD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Graft versus Host Disease (GvHD)</strong></summary>
            <div>
                <ul><li>In patients with typical symptoms, treatment should not be delayed while waiting for biopsy results.</li><li>Acute GvHD usually occurs in the first 3 months post-transplant.</li><li>Treatment is determined by severity and includes corticosteroids and other immunosuppressants.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Neuroendocrine Neoplasms (NENs)</strong></summary>
            <div>
                <ul><li>The majority of GI symptoms in NEN patients do not result from excess hormone production.</li><li>Surgery and systemic treatments (especially somatostatin analogues) frequently cause GI symptoms.</li><li>Gastroenterologists should be involved in the NEN MDT.</li></ul>
                
        <details>
            <summary><strong>Common Causes of Symptoms</strong></summary>
            <div>
                <ul><li>PEI, BAD, and SIBO are common.</li><li>Starting PERT is appropriate without faecal elastase measurement in those with steatorrhoea after starting a somatostatin analogue.</li><li>Prophylactic cholecystectomy should be considered during initial surgery to prevent pancreatitis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Functioning NENs</strong></summary>
            <div>
                <ul><li>Carcinoid Syndrome: Secretory diarrhoea, flushing. Treat with somatostatin analogues (SSAs).</li><li>VIPoma: Profound watery diarrhoea. Treat with fluid/electrolyte replacement, SSAs.</li><li>Gastrinoma (ZES): Peptic ulceration, diarrhoea. Treat with high-dose PPIs.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Mesenteric Fibrosis</strong></summary>
            <div>
                <ul><li>A complication often seen with NENs, causing shrinkage and fixation of the mesentery.</li><li>Can lead to small bowel obstruction and/or ischaemia.</li><li>Abdominal pain can be difficult to manage; requires collaboration with pain/palliative teams.</li></ul>
                
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Early and sustained dietetic input is needed.</li><li>Resection of fibrotic tissue may offer relief but risks short bowel syndrome.</li><li>Long-term home parenteral nutrition is a valid alternative if surgery is too high-risk.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Palliative and End of Life Care</strong></summary>
            <div>
                <ul><li>Focus on remote monitoring of PROMs and optimising quality of life.</li><li>Consider referral to palliative care when there is ≥70% risk of death within 1 year.</li><li>Prioritise minimising pain and avoiding opioid-induced constipation.</li></ul>
                
        <details>
            <summary><strong>Symptom Management</strong></summary>
            <div>
                <ul><li>Diarrhoea/bloating: Consider empirical trial of rifaximin (1 week), bile acid sequestrant (10 days), or PERT (10 days).</li><li>Bleeding: Consider early parenteral iron support.</li><li>Malignant bowel obstruction: Consider corticosteroids and octreotide. A venting gastrostomy can relieve symptoms.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
